438 related articles for article (PubMed ID: 33180317)
1. Real-World Comparative Effectiveness of Canagliflozin Versus Empagliflozin and Dapagliflozin in Patients with Type 2 Diabetes in the United States.
Blonde L; Patel C; Wu B; Chen YW; Pericone CD; Bookhart B
Adv Ther; 2021 Jan; 38(1):594-606. PubMed ID: 33180317
[TBL] [Abstract][Full Text] [Related]
2. A real-world analysis of glycemic control among patients with type 2 diabetes treated with canagliflozin versus dapagliflozin.
Blonde L; Patel C; Bookhart B; Pfeifer M; Chen YW; Wu B
Curr Med Res Opin; 2018 Jun; 34(6):1143-1152. PubMed ID: 29595326
[TBL] [Abstract][Full Text] [Related]
3. Evaluating the costs of glycemic response with canagliflozin versus dapagliflozin and empagliflozin as add-on to metformin in patients with type 2 diabetes mellitus in the United Arab Emirates.
Schubert A; Buchholt AT; El Khoury AC; Kamal A; Taieb V
Curr Med Res Opin; 2017 Jun; 33(6):1155-1163. PubMed ID: 28323512
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of sodium-glucose co-transporter-2 inhibitors in type 2 diabetes mellitus: systematic review and network meta-analysis.
Zaccardi F; Webb DR; Htike ZZ; Youssef D; Khunti K; Davies MJ
Diabetes Obes Metab; 2016 Aug; 18(8):783-94. PubMed ID: 27059700
[TBL] [Abstract][Full Text] [Related]
5. Can we go beyond surrogates?
Drexler A
J Diabetes; 2017 Nov; 9(11):976-977. PubMed ID: 28692750
[TBL] [Abstract][Full Text] [Related]
6. Real-world Canagliflozin Utilization: Glycemic Control Among Patients With Type 2 Diabetes Mellitus-A Multi-Database Synthesis.
Chow W; Miyasato G; Kokkotos FK; Bailey RA; Buysman EK; Henk HJ
Clin Ther; 2016 Sep; 38(9):2071-82. PubMed ID: 27596020
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of empagliflozin versus canagliflozin, dapagliflozin, or standard of care in patients with type 2 diabetes and established cardiovascular disease.
Reifsnider OS; Kansal AR; Gandhi PK; Cragin L; Brand SB; Pfarr E; Fahrbach K; Ustyugova A
BMJ Open Diabetes Res Care; 2021 May; 9(1):. PubMed ID: 33941549
[TBL] [Abstract][Full Text] [Related]
8. A Review of Sodium Glucose Co-transporter 2 Inhibitors Canagliflozin, Dapagliflozin and Empagliflozin.
Syed SH; Gosavi S; Shami W; Bustamante M; Farah Z; Teleb M; Abbas A; Said S; Mukherjee D
Cardiovasc Hematol Agents Med Chem; 2015; 13(2):105-12. PubMed ID: 26549321
[TBL] [Abstract][Full Text] [Related]
9. Canagliflozin, dapagliflozin and empagliflozin monotherapy for treating type 2 diabetes: systematic review and economic evaluation.
Johnston R; Uthman O; Cummins E; Clar C; Royle P; Colquitt J; Tan BK; Clegg A; Shantikumar S; Court R; O'Hare JP; McGrane D; Holt T; Waugh N
Health Technol Assess; 2017 Jan; 21(2):1-218. PubMed ID: 28105986
[TBL] [Abstract][Full Text] [Related]
10. Benefits of SGLT2 Inhibitors Beyond Glycemic Control - A Focus on Metabolic, Cardiovascular and Renal Outcomes.
Minze MG; Will KJ; Terrell BT; Black RL; Irons BK
Curr Diabetes Rev; 2018; 14(6):509-517. PubMed ID: 28814245
[TBL] [Abstract][Full Text] [Related]
11. The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes.
Whalen K; Miller S; Onge ES
Clin Ther; 2015 Jun; 37(6):1150-66. PubMed ID: 25891804
[TBL] [Abstract][Full Text] [Related]
12. Sodium-glucose co-transporter 2 inhibitors for type 2 diabetes mellitus: An overview for the primary care physician.
Dandona P; Chaudhuri A
Int J Clin Pract; 2017 May; 71(5):. PubMed ID: 28440009
[TBL] [Abstract][Full Text] [Related]
13. Cost of Glycemic Target Achievement with Sodium Glucose Co-transporter 2 Inhibitors in Patients with Type 2 Diabetes in the UK.
Evans M; Achha S; Neslusan C
Diabetes Ther; 2017 Oct; 8(5):1175-1185. PubMed ID: 28948541
[TBL] [Abstract][Full Text] [Related]
14. SGLT-2 receptor inhibitors for treating patients with type 2 diabetes mellitus: a systematic review and network meta-analysis.
Shyangdan DS; Uthman OA; Waugh N
BMJ Open; 2016 Feb; 6(2):e009417. PubMed ID: 26911584
[TBL] [Abstract][Full Text] [Related]
15. HBA1C CONTROL AND COST-EFFECTIVENESS IN PATIENTS WITH TYPE 2 DIABETES MELLITUS INITIATED ON CANAGLIFLOZIN OR A GLUCAGON-LIKE PEPTIDE 1 RECEPTOR AGONIST IN A REAL-WORLD SETTING.
Wysham CH; Pilon D; Ingham M; Lafeuille MH; Emond B; Kamstra R; Pfeifer M; Lefebvre P
Endocr Pract; 2018 Mar; 24(3):273-287. PubMed ID: 29547044
[TBL] [Abstract][Full Text] [Related]
16. Real-world evaluation of glycemic control among patients with type 2 diabetes mellitus treated with canagliflozin versus dipeptidyl peptidase-4 inhibitors.
Thayer S; Chow W; Korrer S; Aguilar R
Curr Med Res Opin; 2016 Jun; 32(6):1087-96. PubMed ID: 26938635
[TBL] [Abstract][Full Text] [Related]
17. Sodium glucose co-transporter 2 inhibitors and cardiovascular event protections: how applicable are clinical trials and observational studies to real-world patients?
Shao SC; Lin YH; Chang KC; Chan YY; Hung MJ; Kao Yang YH; Lai EC
BMJ Open Diabetes Res Care; 2019 Dec; 7(1):. PubMed ID: 32043472
[TBL] [Abstract][Full Text] [Related]
18. An observational study of glycemic control in canagliflozin treated patients.
Meckley LM; Miyasato G; Kokkotos F; Bumbaugh J; Bailey RA
Curr Med Res Opin; 2015 Aug; 31(8):1479-86. PubMed ID: 25986535
[TBL] [Abstract][Full Text] [Related]
19. Comparative Genitourinary Safety of In-class Sodium-Glucose Cotransporter-2 Inhibitors among Patients with Heart Failure with Preserved Ejection Fraction: A Cohort Study.
Riaz M; Guo J; Smith SM; Dietrich EA; Winchester DE; Park H
Am J Cardiovasc Drugs; 2024 May; 24(3):455-464. PubMed ID: 38691312
[TBL] [Abstract][Full Text] [Related]
20. Selective sodium-glucose cotransporter-2 inhibitors in the improvement of hemoglobin and hematocrit in patients with type 2 diabetes mellitus: a network meta-analysis.
Luo Y; Bai R; Zhang W; Qin G
Front Endocrinol (Lausanne); 2024; 15():1333624. PubMed ID: 38362282
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]